Efficacy of Novel Hemagglutinin-Neuraminidase Inhibitors BCX 2798 and BCX 2855 against Human Parainfluenza Viruses In Vitro and In Vivo

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 5, 2004, Pages 1495-1502

  Alymova, Irina V ^a   Taylor, Garry ^a   Takimoto, Toru ^a   Lin, Tsu Hsing ^b   Chand, Pooran ^b   Babu, Y Sudhakara ^b   Li, Chenghong ^c   Xiong, Xiaoping ^c   Portner, Allen ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

^c BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BCX 2798; BCX 2855; HN PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LUNG; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; RESPIRATORY SYSTEM; RNA VIRUS INFECTION; SENDAI VIRUS; VIRUS INHIBITION; VIRUS TITRATION;

ANIMALS; ANTIVIRAL AGENTS; AZIDES; ENZYME INHIBITORS; FEMALE; HEMAGGLUTININS; HEXURONIC ACIDS; HUMANS; LLC-PK1 CELLS; LUNG; MICE; NEURAMINIDASE; PARAINFLUENZA VIRUS 1, HUMAN; PARAINFLUENZA VIRUS 2, HUMAN; PARAINFLUENZA VIRUS 3, HUMAN; PARAMYXOVIRIDAE INFECTIONS; RECOMBINANT PROTEINS; SENDAI VIRUS; SULFONAMIDES; SWINE; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

EID: 2142698613     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.5.1495-1502.2004     Document Type: Article

References (44)

1. Appell, L. H., R. M. Kovatch, J. M. Reddecliff, and P. J. Gerone. 1971. Pathogenesis of Sendai virus infection in mice. Am. J. Vet. Res. 32:1835-1841.
2. Bianta, S., C. D. Parker, S. L. Ananth, L. L. Horn, K. Andries, P. Chand, P. L. Kotian, A. Denghani, Y. El-Kattan, T. Lin, T. L. Hutchison, J. A. Montogomery, D. L. Kellog, and Y. S. Babu. 2001. Comparison of the anti-influenza activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167.
3. Bousse, T., T. Takimoto, W. L. Gorman, T. Takahashi, and A. Portner. 1994. Regions on the hemagglutinin-neuraminidase proteins of human parainfluenza virus type-1 and Sendai virus important for membrane fusion. Virology 204:506-514.
4. Bousse, T., T. Takimoto, T. Matrosovich, and A. Portner. 2001. Two regions of the P protein are required to be active with the L protein for human parainfluenza virus type 1 RNA polymerase activity. Virology 283:306-314.
5. Chanock, R. M., B. R. Murphy, and P. L. Collins. 2001. Parainfluenza viruses, p. 1341-1379. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott/The Williams & Wilkins Co., Philadelphia, Pa.
6. Collier, A. M., and W. A. Clyde, Jr. 1977. Model systems for studying the pathogenesis of infections causing bronchiolitis in man. Pediatr. Res. 11:243-246.
7. Cox, D. R., and D. Oakes. 1984. Analysis of survival data. Chapman & Hall, London, United Kingdom.
8. Crennell, S., T. Takimoto, A. Portner, and G. Taylor. 2000. Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase. Nat. Struct. Biol. 7:1068-1074.
9. Degre, M., and H. Rollag, Jr. 1980. Pathogenesis of Sendai virus infection in mice: on the possible role of interferon on the development of disease. Acta Pathol. Microbiol. Scand. 88:177-181.
10. Du Bridge, R. Tang, H. C. Hsia, P. M. Leong, J. H. Miller, and M. P. Calos. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 6:379-387.
11. Gubareva, L. V., C. R. Penn, and R. G. Webster. 1995. Inhibition of replication of avian influenza viruses by neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 212:323-330.
12. Hayden, F. G., A. D. Osterhaus, J. J. Treanor, D. M. Fleming, F. Y. Aoki, K. G. Nicholson, A. M. Bohnen, H. M. Hirst, O. Keene, K. Wightman, et al. 1977. Efficacy and safety of the neuraminidase inhibitor zanamovir in the treatment of influenza virus infections. N. Engl. J. Med. 337:874-880.
13. Hayden, F. G., J. J. Treanor, R. S. Fritz, M. Lobo, R. F. Betts, M. Miller, N. Kinnersley, R. G. Mills, P. Ward, and S. E. Straus. 1999. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282:1240-1246.
14. Henrickson, K. J., S. M. Kuhn, and L. L. Savatski. 1994. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin. Infect. Dis. 18:770-779.
15. Horvath, C. M., R. G. Paterson, M. A. Shaughnessy, R. Wood, and R. A. Lamb. 1992. Biological activity of paramyxovirus fusion protein: factors influencing formation of syncytia. J. Virol. 66:4564-4569.
16. Hu, X., R. Ray, and R. W. Compans. 1992. Functional interaction between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses. J. Virol. 66:1528-1534.
17. Kaplan, E. L, and P. Meier. 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-481.
18. Kato, A., Y. Sakai, T. Shioba, T. Kondo, M. Nakanishi, and Y. Nagai. 1996. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells 1:569-579.
19. Kim, C. U., W. Lew, M. A. Williams, H. Wu, L. Zhang, X. Chen, P. A. Escarpe, D. B. Mendel, W. C. Laver, and R. C. Stevens. 1998. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J. Med. Chem. 41:2451-2460.
20. Knott, A. M., C. E. Long, and C. B. Hall. 1994. Parainfluenza viral infections in pediatric outpatients: seasonal patterns and clinical characteristics. Pediatr. Infect. Dis. J. 13:269-273.
21. Lamb, R. A., and D. Kolakofsky. 1996. The paramyxoviruses, p. 577-604. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
22. Markwell, M. A. K. 1991. New frontiers opened by the exploration of host cell receptors, p. 407-425. In D. W. Kingsbury (ed.), The paramyxoviruses. Plenum Press, Inc., New York, N.Y.
23. Marx, A., T. J. Torok, R. C. Holman, M. J. Clarke, and L. J. Anderson. 1997. Pediatric hospitalization for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J. Infect. Dis. 176:1423-1427.
24. Mascoli, C. C., D. P. Metzgar, E. J. Larson, A. A. Fuscaldo, and T. A. Gower. 1975. An animal model for studying infection and immunity to and attenuation of human parainfluenza viruses. Dev. Biol. Stand. 28:414-421.
25. Mendel, D. B., C. Y. Tai, P. A. Escarpe, W. Li, R. W. Sidwell, J. H. Huffman, C. Sweet, K. J. Jakeman, S. Merson, S. A. Lacy, N. Lew, M. A. Williams, L. Zhang, M. S. Chen, N. Bischofberger, and C. U. Kim. 1998. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42:640-646.
26. Murphy, T. F., E. J. Dubovi, and W. A. Clyde, Jr. 1981. The cotton rat as an experimental model of human parainfluenza virus 3 disease. Exp. Lung Res. 2:97-109.
27. Potier, M., L. Mameli, M. Belishem, L. Dallaire, and S. B. Melancon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
28. Reed, G., P. H. Jewett, J. Thompson, S. Tollefson, and P. F. Wright. 1997. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J. Infect. Dis. 175: 807-813.
29. Ryan, D. M., J. Ticehurst, M. H. Dempsey, and C. R. Penn. 1994. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob. Agents Chemother. 38:2270-2275.
30. SAS Institute. 1999. SAS/STAT user's guide, version 8, vol. 2. SAS Institute, Inc., Cary, N.C.
31. Sidwell, R. W., J. H. Huffman, D. L. Barnard, K. W. Bailey, M.-H. Wong, A. Morrison, T. Synergaard, and C. U. Kim. 1998. Inhibition of influenza virus infection in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antivir. Res. 37:107-120.
32. Stone-Hulslander, J., and T. G. Morrison. 1997. Detection of an interaction between the HN and F proteins in Newcastle disease virus-infected cells. J. Virol. 71:6287-6295.
33. Takimoto, T., G. L. Taylor, S. L. Crennell, R. A. Scroggs, and A. Portner. 2000. Crystallization of Newcastle disease virus hemagglutinin-neuraminidase glycoprotein. Virology 270:208-214.
34. Takimoto, T., G. L. Taylor, H. C. Connaris, S. J. Crennell, and A. Portner. 2002. Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion. J. Virol. 76:13028-13033.
35. Tao, T., F. Davoodi, C. J. Cho, M. H. Skiadopoulos, A. P. Durbin, P. L. Collins, and B. R. Murphy. 2000. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine 18:1359-1366.
36. Taylor, N. R., and M. von Itzstein. 1994. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J. Med. Chem. 37:616-624.
37. Tennant, J. R. 1964. Evaluation of the trypan blue technique for determination of cell viability. Transplantation 2:685-694.
38. Thompson, S. D., W. G. Laver, K. G., Murti, and A. Portner. 1988. Isolation of a biologically active soluble form of the hemagglutinin-neuraminidase protein of Sendai virus. J. Virol. 62:4653-4660.
39. Varghese, J. N., W. G. Laver, and P. M. Colman. 1983. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. Nature 303:35-40.
40. Venables, W. N., and B. D. Ripley. 1997. Modern applied statistics, p. 223-242. Springer-Verlag, New York, N.Y.
41. von Itzstein, M., W.-Y. Wu, G. B. Kok, M. S. Pegg, J. C. Dyason, B. Jin, T. van Plan, M. L. Smythe, H. F. White, S. W. Oliver, P. M. Colman, J. N. Varghese, D. M. Ryan, J. M. Woods, R. C. Bethell, V. J. Hothman, J. M. Cameron, and C. R. Penn. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423.
42. Woods, J. M., R. C. Bethell, J. A. V. Coates, N. Healy, S. A. Hiscox, B. A. Pearson, D. M. Ryan, J. Ticehurst, J. Tilling, S. M. Walcott, and C. R. Renn. 1993. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37:1473-1479.
43. Yao, Q., X. Hu, and R. W. Compans. 1997. Association of the parainfluenza virus fusion and hemagglutinin-neuraminidase glycoproteins on cell surfaces. J. Virol. 71:650-656.
44. Zurcher, C., J. D. Burek, M. C. Van Nunen, and S. P. Meihuizen. 1977. A naturally occurring epizootic caused by Sendai virus in breeding and aging rodent colonies. I. Infection in the mouse. Lab. Anim. Sci. 27:955-962.